Neurology 84 , 11741176 (2015)
In principle, synergy is plausible in a few situations: Complementary pathways (e.g., appetite control + strength training adherence) Non-overlapping side-effect profiles Clear outcome tracking (so you can actually attribute effects) Where it tends to fall apart: Redundancy (two agents trying to push the same pathway) Hormonal axis pressure (especially GH/IGF-1 axis stacking) Long timelines with weak evidence (people run stacks for months because its peptides, not because outcomes justify it) For the rest of this article, Ill treat each stack as a clinical hypothesis and ask a simple question: If this were my patient, what would I be confident saying based on human evidenceand what would I label unknown? The 7 stacks people search for most (and what the evidence really supports) Quick comparison table Now, lets go stack by stack
Posted by Amanda Waesch & Adrianna Globokar
According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), itch-driven scratching damages the skin barrier further, increasing inflammation and infection risk in atopic dermatitis patients
People use BPC-157 for: Tendonitis Partial tendon tears Post-surgical tendon repair Tennis elbow Achilles issues Rotator cuff problems Typical approach: 250-500 mcg daily, injected near the affected tendon
Your mileage may vary, but from what Ive seen, most people report the same timeline
